Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.
A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.
AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.
The majority of the layoffs will be in the US.
Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like meals, travel, gifts, consulting and research
The way in which consumers will perceive adaptive marketing is going to depend crucially on our motives.
The differences that can be made by meaningful use are ones that need some time to make themselves felt
Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.
The company is calling the move a withdrawal, as opposed to a recall.
The meningitis and encephalitis medications earned a combined $300 million last year.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
Missed MM&M's Skill Sets Live event on Engaging Patients? We're now giving you a second chance to get up to speed! Click here to access this insightful e-book with all the key take-aways.